Vanda Pharmaceuticals Inc. - Common Stock (VNDA)

AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas.

The company argues that regulators relied on narrow study populations and overlooked major data inconsistencies, raising concerns about patient safety.

FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the agency's review process.

HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology.

A regulator's decision drained the market's enthusiasm for the company.

The FDA rejected Vanda Pharmaceuticals' new drug application for tradipitant to treat gastroparesis, citing the need for more studies despite delays in its review process. Vanda argues the drug meets efficacy standards and plans to continue pursuing approval.

Vanda Pharmaceuticals shares decline as Future Pak withdraws acquisition offer following Vanda's rejection and lack of response.

Cycle Pharmaceuticals wants to acquire Vanda Pharmaceuticals for $8 per share, or $466 million. Cycle focuses on rare neurological conditions.